Skip to Main Content

Advertisement intended for health care professionals

American Society of Hematology Logo Open Menu
Cart
header search
Search
Skip Nav Destination

On Location

Updates from major medical meetings in the field of hematology/oncology
Five-Year Results of Patients With Del(17p)-Mutated, Treatment-Naïve CLL/SLL Treated with Zanubrutinib in the SEQUOIA Trial Free
Anna Azvolinsky, PhD
May 28, 2025
Results Detail Comparison of Patients With R/R CLL/SLL in Liso-Cel TRANSCEND CLL 004 Trial With Real-World Cohort Free
Anna Azvolinsky, PhD
May 28, 2025
PVEK Shows Promising Efficacy in Blastic Plasmacytoid Dendritic Cell Neoplasm Free
Thomas R. Collins
May 28, 2025
Patients With R/R CLL/SLL Achieve Tumor Response With DZD8586 Free
Thomas R. Collins
May 27, 2025
MRD Negativity Associated with PFS and OS Benefit in DREAMM-8 Multiple Myeloma Trial Free
Anna Azvolinsky, PhD
May 27, 2025
Zanubrutinib Plus Venetoclax Shows Efficacy in Treatment-Naïve CLL Free
Thomas R. Collins
May 27, 2025
Clonal Hematopoiesis Associated With Cytopenias After CAR-T Therapy for MM Free
Katie Robinson
March 12, 2025
Teclistamab Safe for Treating Patients with R/R MM with Renal Impairment Free
Thomas R. Collins
February 12, 2025
Study of LBCL Confirms Prognostic Value of ctDNA in Second-Line Liso-Cel Versus Standard of Care Free
Katie Robinson
February 12, 2025
Extramedullary Disease Helps Predict Immune Effector Cell Toxicities After CAR-T in MM Free
Thomas R. Collins
February 12, 2025
Clonal Hematopoiesis May Prolong Cytopenias After CAR-T Therapy for MM Free
Katie Robinson
February 11, 2025
CAR-T Shows Acceptable Efficacy, Safety in Phase II R/R T-ALL/LBL Study Free
Katie Robinson
February 11, 2025
Physical Function Can Help Gauge ICANS Risk, Study Finds Free
Thomas R. Collins
February 11, 2025
Non-Viral, Allogeneic BCMA-Directed CAR-T Therapy Eliminates Bridging in R/R MM Free
Lara C. Pullen, PhD
February 10, 2025
Multimodal Machine Learning Boosts CAR-T Outcome Prediction in LBCL Free
Thomas R. Collins
February 10, 2025
Cilta-Cel Treatment in Lenalidomide-Refractory MM Results in High Rates of MRD Negativity Free
Katie Robinson
February 10, 2025
Study Highlights Characteristics of Post-CAR-T Treatment–Related Myeloid Neoplasms Free
Katie Robinson
February 6, 2025
IL-15 Agonist Boosts Response in Phase II LBCL CAR-T Trial Free
Thomas R. Collins
February 6, 2025
Predicting Response to Obe-Cel in Patients With R/R B-ALL Free
Lara C. Pullen, PhD
February 6, 2025
Daratumumab Plus Lenalidomide Shows MRD, PFS Benefit in Newly Diagnosed MM After AHCT in Clinically Relevant Subgroups Free
Katie Robinson
December 17, 2024

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
June 2025

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2025 by American Society of Hematology
 
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals